SCHEMBL30186358

SCHEMBL30186358

Cn1ccc(=O)c2ccc(O)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
CYP2C9 P11712 2/20 0.44
KDM6A O15550 1/20 0.44
KDM4A O75164 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM5C P41229 1/20 0.44
KDM2B Q8NHM5 1/20 0.44
DOHH Q9BU89 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
FTO Q9C0B1 1/20 0.41
ESR1 P03372 2/20 0.39
GSK3B P49841 1/20 0.38
TTR P02766 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HSD17B3 P37058 3/20 0.36
GAA P10253 3/20 0.36
HPGD P15428 3/20 0.36
GLA P06280 2/20 0.36
CDK4 P11802 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186396 0.85 KDM4E (0.44) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL5022143 0.79 KDM4E (0.41) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL6050596 0.79 MAT2A (0.44) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL15992161 0.79 KDM4E (0.46) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL25339009 0.79 KDM4E (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL30544099 0.79 KDM4E (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL10627492 0.78 ATM (0.47) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL22774031 0.78 GSK3B (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL29576495 0.78 GSK3B (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
Hydrochloric Acid SCHEMBL29744368 0.76 GSK3B (0.37) KDM4ECYP2C9KDM6AKDM4ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH KDM4E 3648/4885CYP2C9 1135/4885KDM6A 3814/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885CYP2C9 4695/4885KDM6A 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.